	Les Charges D'Exploitation		Date
Acadia Pharmaceuticals	USD 266.6M	23.72M	2025-12
Adma Biologics	USD 83.21M	4.02M	2025-09
ALKERMES	USD 326.44M	1.41B	2025-12
Alterity Therapeutics Limited	AUD 7.78M	3M	2023-06
AstraZeneca	USD 12.53B	4.16B	2025-12
BioCryst Pharmaceuticals	USD -387.89M	33.7M	2025-09
Bristol-Myers Squibb	USD 8.3B	10.25B	2025-12
Cipla	INR 60.98B	1.06B	2025-12
Clal Biotechnology	ILS 5.15M	9.47M	2022-12
Compugen	USD 9.78M	90K	2025-09
CSL	USD 5.7B	2.82B	2025-12
Eli Lilly	USD 10.31B	1.09B	2025-12
Esperion Therapeutics	USD 67.66M	3.6M	2024-09
GlaxoSmithKline	GBP 7.18B	1.42B	2025-12
Grifols	EUR 1.77B	22.04M	2025-09
Halozyme Therapeutics	USD 211.07M	74.73M	2025-12
Ionis Pharmaceuticals	USD 418M	101.1M	2025-12
J&J	USD 18.97B	2.38B	2025-12
Merck	USD 10.16B	558M	2025-12
Minerva Neurosciences	USD 4.52M	155.46K	2024-12
Neurocrine Biosciences	USD 577.6M	22M	2025-12
Novartis	USD 9.86B	115M	2025-09
Novavax	USD 218.53M	34.86M	2024-09
Pfizer	USD 12.91B	79.89B	2025-12
Roche Holding	CHF 21.01B	10.84B	2025-12
Sanofi	EUR 10.51B	1.21B	2025-12
Takeda	JPY 1.02T	400.98B	2025-12
Vanda Pharmaceuticals	USD 466M	20.33M	2025-09

Minerva Neurosciences Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2026.